Physician profile

Zaineb Daud

Neurology (Psychiatry & Neurology) · Philadelphia, MS

NPI 1568468908

$8,191.38

in general payments reported to CMS, 2019-2025

41 companies · $1,519 in 2025

The $1,519 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

See the full distribution for Neurology (Psychiatry & Neurology)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,235.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Acadia Pharmaceuticals INC $1,150.20 2019-2025 Nuplazid
Lilly USA, LLC $938.18 2019-2025 Kisunla, Emgality, Amyvid
Teva Pharmaceuticals USA, INC. $732.46 2019-2024 Austedo Xr, Ajovy, Austedo
Pfizer INC. $570.01 2023-2025
Sk Life Science, INC. $539.89 2020-2024
Novartis Pharmaceuticals Corporation $411.81 2019-2025
Mallinckrodt Hospital Products INC. $300.54 2023-2025 Acthar
Abbvie INC. $282.88 2021-2025 Ubrelvy, Qulipta
Kyowa Kirin, INC. $281.29 2020-2022
Lundbeck LLC $249.08 2022-2025 Vyepti, Rexulti
Sunovion Pharmaceuticals INC. $245.47 2019-2022
Genzyme Corporation $211.74 2019-2023
Sumitomo Pharma America, INC. $205.40 2023-2024 Aptiom
Ani Pharmaceuticals, INC. $203.51 2024-2025 Purified Cortrophin Gel
Avanir Pharmaceuticals, INC. $175.91 2019-2021
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Neurocrine Biosciences, INC. $171.88 2020-2021
Supernus Pharmaceuticals, INC. $168.54 2019-2020
Catalyst Pharmaceuticals, INC. $139.71 2022-2025
Amgen INC. $137.65 2020-2023 Aimovig
Otsuka America Pharmaceutical, INC. $107.19 2023-2025 Rexulti, Nuedexta
Argenx US, INC. $95.07 2024-2025 Vyvgart Hytrulo
Alexion Pharmaceuticals, INC. $94.15 2022
Ucb, INC. $89.71 2019-2021
Grifols USA, LLC $84.22 2022-2024 Gamunex-C, Xembify
Csl Behring $79.95 2019-2025 Hizentra
Merz Pharmaceuticals, LLC $66.92 2025 Xeomin, Inbrija
Ge Healthcare $59.62 2019-2021
Bayer Healthcare Pharmaceuticals INC. $51.13 2021
Upsher-Smith Laboratories LLC $39.77 2022
Corium, LLC $38.61 2022-2023 Adlarity
Mdd US Operations, LLC $38.34 2020-2022
Biohaven Pharmaceuticals, INC. $33.23 2021
Biohaven Pharmaceutical Holding Company LTD. $27.15 2022
Boston Scientific Corporation $26.51 2022
Acorda Therapeutics, INC $25.17 2023 Ampyra
Amneal Pharmaceuticals LLC $25.02 2019
Allergan, INC. $23.69 2020-2021
Axsome Therapeutics, INC. $20.08 2025 Symbravo
Averitas Pharma INC. $18.39 2025 Qutenza
Sanofi-Aventis U.S. LLC $15.93 2020
Greenwich Biosciences, INC. $15.38 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Zaineb Daud

$8,191.38

in general payments reported 2019-2025

Years
2019-2025
Top company
Acadia Pharmaceuticals INC
Context
The $1,519 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

https://glasscript.com/doctor/1204772/zaineb-daud

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.